Neurocrine Biosciences, Inc. (NBIX)
$135.13-4.41%Close
SELLRECOVERY · day 28
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $13.6B
- Beta
- 0.40
- P/E (TTM)
- 19.17
- Short % float
- 5.83%
- Days to cover
- 4.0
- SI change
- +17.9%
- 1W
- -7.13%
- 1M
- -14.05%
- vs SPY 1W
- -6.99%
- vs SPY 1M
- -16.56%
Industry peers
FMP comparable companies · ranked by market cap
- JAZZSELLJazz Pharmaceuticals plc$13.7BBEARQ 24$218.42-2.93%
- AXSMSELLAxsome Therapeutics, Inc.$8.7BCRISISQ 34$168.35-5.83%
- HLBBFH. Lundbeck A/S$5.4B$6.76
- ACADSELLAcadia Pharmaceuticals Inc.$3.4BCRISISQ 17$19.78-4.07%
- SUPNBUYSupernus Pharmaceuticals, Inc.$2.5BRECOVERYQ 26$42.67-1.87%
- BHVNSELLBiohaven Ltd.$1.8BCRISISQ 16$12.08-3.30%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.5BCRISISQ 24$30.65-3.85%
- GHRSSELLGH Research PLC$1.4BCRISISQ 14$21.11-5.84%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NBIX?
- LOPJLB’s latest quantitative signal on Neurocrine Biosciences, Inc. (NBIX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is NBIX in?
- Neurocrine Biosciences, Inc. (NBIX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Neurocrine Biosciences, Inc. (NBIX) do?
- Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental …